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Abstract
Considerable advances in oncology over recent decades have led to improved survival, while raising concerns about long-term 
consequences of anticancer treatments. In patients with breast or prostate malignancies, bone health is a major issue due to 
the high risk of bone metastases and the frequent prolonged use of hormone therapies that alter physiological bone turnover, 
leading to increased fracture risk. Thus, the onset of cancer treatment-induced bone loss (CTIBL) should be considered by 
clinicians and recent guidelines should be routinely applied to these patients. In particular, baseline and periodic follow-up 
evaluations of bone health parameters enable the identification of patients at high risk of osteoporosis and fractures, which 
can be prevented by the use of bone-targeting agents (BTAs), calcium and vitamin D supplementation and modifications of 
lifestyle. This review will focus upon the pathophysiology of breast and prostate cancer treatment-induced bone loss and the 
most recent evidence about effective preventive and therapeutic strategies.
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Introduction
Advances in systemic cancer therapies and diagnostic tech-
niques have led to consistent improvements in cancer sur-
vival, and, as a result, the long-term sequelae of cancer treat-
ment have become an increasingly important consideration. 
Treatment-related adverse effects significantly impact the 
quality of life of patients, many of whom will live for years 
following their cancer diagnosis. They are also associated 
with significant economic costs to health and social care 
providers.
Bone health is an area of particular importance for 
patients with breast and prostate tumours. These are the 
commonest malignancies to affect females and males, 
respectively. More than 460,000 women are diagnosed with 
breast cancer (BC) in Europe each year, and BC is responsi-
ble for 130,000 deaths [1]. More than 420,000 men are diag-
nosed with prostate cancer (PC) in Europe each year, with 
more than half of cases occurring in men aged over 70 years 
[2]. Survival rates from both BC and PC have significantly 
improved over the past 40 years as a result of both treatment 
advances and earlier diagnosis, due to improved diagnostic 
techniques and screening campaigns.
In BC and PC, both the disease itself and the treatments 
pose specific challenges to skeletal integrity. This review 
will focus upon bone loss that occurs as a direct result of 
cancer therapy (cancer treatment-induced bone loss, CTIBL) 
for BC and PC. We will describe the factors that regulate 
bone remodelling processes, the pathophysiology and clini-
cal complications of CTIBL. Evidence to support the use of 
bone-targeted agents (BTAs) will also be discussed, along 
with current guidelines for CTIBL management.
Influence of Sex Steroids on Bone
Both androgens and oestrogens have important roles in bone 
growth and maturation, and maintenance of skeletal integ-
rity. However, accumulating evidence suggests a role for 
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other reproductive hormones, such as activins and inhibins, 
in the preservation of bone health.
Androgens
Testosterone is the most abundant circulating androgen in 
men, 95% of which is secreted by the testis. The remain-
ing 5% is formed from the enzymatic conversion of adrenal 
androgens dehydroepiandrosterone (DHEA) and DHEA 
sulphate (DHEAS) [3]. In women, the major circulating 
androgens are produced by the adrenal glands and ovaries 
and include DHEAS and DHEA, androstenedione (pro-
androgens), testosterone and dihydrotestosterone (DHT). 
Female testosterone production also occurs via peripheral 
aromatisation of androstenedione. In both men and women, 
the majority of circulating testosterone is protein bound (to 
either sex hormone-binding globulin or albumin).
Testosterone may act directly on androgen receptors 
(AR), or indirectly via aromatisation to oestradiol and acti-
vation of oestrogen receptors (ER). The indirect actions of 
testosterone may also occur following conversion to the 
more potent DHT by 5α-reductase in peripheral tissues [4].
In bone, androgens exert direct effects on growth plate 
chondrocytes and promote longitudinal bone growth [5]. 
Both testosterone and DHT stimulate the proliferation of 
osteoblast precursors via AR signalling [6]. Binding of 
androgens with AR also upregulates osteoblast AR expres-
sion and promotes their differentiation [7]. Androgens also 
prevent osteoblast and osteocyte apoptosis and regulate 
osteoclast activity by inhibiting the interaction of receptor 
activator of nuclear factor kappa-B ligand (RANK-L) with 
its receptor (RANK), expressed on osteoclast precursors 
[8, 9]. Bone formation is promoted by androgen-mediated 
upregulation of growth factors, such as insulin-like growth 
factor and transforming growth factor beta, TGFβ [6]; on the 
other hand, downregulation of interleukin 6 inhibits osteo-
clast activity [10] through the reduction in levels of osteo-
protegerin (OPG), which is produced by osteoblasts and acts 
as a soluble decoy receptor to RANK-L [11].
Oestrogens
The net action of oestrogens on bone is to decrease bone 
resorption. Their actions are exerted via ERα and ERβ recep-
tors, expressed by osteoblasts and osteoclasts. Oestrogens 
increase osteoblast number and activity, inhibit the matura-
tion of osteoclast precursors (via increased OPG production) 
and also cause osteoclast apoptosis [12, 13]. Oestrogen defi-
ciency is known to increase the rate of osteocyte apoptosis 
with a consequent increase in skeletal fragility [14, 15].
In women, oestrogens are critical for the maintenance 
of normal bone mass. At the menopause, loss of ovarian 
follicular activity causes a significant fall in circulating 
oestrogens, with a consequent disruption of bone remodel-
ling. The most rapid bone loss occurs in the first 3 years 
post-menopause (2–5%/year), after which skeletal metabo-
lism becomes “acclimatised” to the low-oestrogen environ-
ment and bone loss slows to around 0.5–1.0% per annum. 
A greater proportion of bone loss occurs at sites containing 
trabecular bone (such as the spine) than cortical sites (such 
as the hip) [16].
Oestrogens have been identified as the sex steroids pri-
marily responsible also for the regulation of bone resorption 
in men. In studies of young male patients unable to produce 
or respond to oestrogens, there was an increased rate of bone 
turnover and osteopaenia [17, 18]. Both oestrogens and tes-
tosterone are known to be important in the regulation of 
male bone formation [19].
Activins and Inhibins
Activins and inhibins belong to the TGFβ superfamily and 
exert their biological activity by interacting with a type II 
serine/threonine kinase receptor; once the latter associates 
with the corresponding type I receptor, an intracellular path-
way is activated, leading to the regulation of DNA transcrip-
tion, mediated by Smad proteins [20].
Activin A and B are homodimeric peptides, made up of 
βA and βB subunits, respectively, and regulated by gon-
adotropins from the pituitary. Activin A is produced in the 
gonad, while activin B is secreted by the pituitary gland 
itself; in the circulation, they are bound to follistatin in 
order to prevent excessive interaction with the activin type 
II receptor (ACTRII). Interestingly, neither activin A nor fol-
listatin serum levels vary according to the menopausal status 
[21]. BC cells have been shown to produce activin, which in 
turn inhibits the proliferation of ER + tumour cell lines [22]; 
however, its role in the establishment of bone metastases has 
not been clarified yet. Moreover, while its capability to pro-
mote osteoclastogenesis via RANK upregulation has been 
ascertained, conflicting data exist about the role of activin 
in osteoblastogenesis [21].
Inhibin A and B are heterodimeric proteins, including 
αβA or αβB subunits. Due to their capability to prevent the 
interaction of activin with ACTRII, inhibins suppress gon-
adotropin secretion from the pituitary gland. Inhibin B levels 
tend to decline with age in both women and men, thus repre-
senting a good marker for fertility [23]. Similarly to activins, 
inhibins are secreted by BC cells [24] although their role in 
carcinogenesis seems contradictory. As activin inhibitors, 
one would expect them to promote tumour cell prolifera-
tion, but in vivo and clinical data suggest a possible tumour-
suppressive activity [22]. With respect to bone turnover, this 
seems to be counteracted by inhibins through the suppres-
sion of both osteoblastogenesis and osteoclastogenesis [21]. 
Moreover, in a cross-sectional study involving 188 women 
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with different ages (from 21 to 85 years), inhibins turned out 
as the best predictors of bone marker fluctuations, potentially 
able to indicate the initial bone loss that characterises the 
perimenopausal period, even before sex steroid and gonado-
tropin variations could be detected [25].
Bone Loss in Prostate Cancer
Pathophysiology
The growth of PC is initially androgen dependant, and the 
cornerstone of treatment is androgen deprivation therapy 
(ADT). This is most often achieved by the administration of 
luteinising hormone-releasing hormone (LHRH) agonists, 
LHRH antagonists and antiandrogens. ADT provides excel-
lent initial disease control in virtually all patients; however, 
many of them subsequently develop castration resistance. 
Following the initiation of ADT, sex steroid levels decrease 
rapidly and significantly, reaching a nadir within 2–4 weeks 
(less than 5 and 20% of normal testosterone and oestrogen 
levels, respectively). This leads to an accelerated and disor-
ganised bone turnover process and net bone loss that is most 
rapid during the first year of ADT (studies have reported 
between 5 and 10% loss of bone mineral density, BMD) 
[26–28]. BMD loss also continues gradually throughout 
ADT duration. In a study of 390 men aged 54–89, the preva-
lence of osteoporosis was found to be 35% in hormone-naïve 
patients, 43% after 2 years of ADT and 81% after 10 years 
of ADT [29].
The pattern of CTIBL associated with ADT has been 
shown to differ from that seen with other conditions, being 
more likely to affect the radius than the hip or spine [30]. 
However, recent evidence suggests that this phenomenon 
could be partially attributed to the frequent overestimation 
of central BMD in men with skeletal degenerative disorders, 
which commonly occur in the elderly. On the other hand, 
densitometers have been found to over-read radius osteopo-
rosis when using a male normative database, and thus fore-
arm BMD should be re-analysed and evaluated according to 
larger normative databases [31].
In addition to ADT, men with newly diagnosed hormone-
sensitive metastatic PC may receive chemotherapy [32]. 
Docetaxel is given for 18 weeks, along with daily 10 mg 
prednisolone and 24 mg dexamethasone every 3 weeks. It 
is well established that long-term use of glucocorticoids is 
associated with osteoporosis; indeed, it is the most common 
cause of secondary osteoporosis. Evidence suggests that the 
risk of hip and vertebral fractures increases up to 7- and 
17-fold, respectively, when doses equivalent to 10–12 mg 
prednisolone are given for more than 3 months. The risk of 
fracture is also increased even when small (2.5–3 mg) daily 
doses are given [33]. No studies to date have investigated the 
impact of the combination of chemotherapy and glucocorti-
coids with ADT on BMD and fracture risk in men with PC.
Clinical Sequelae
CTIBL that is associated with ADT exponentially increases 
the risk of fracture. Indeed, the loss of 10–15% of BMD 
doubles the fracture risk [34] and men receiving ADT for PC 
are five times more likely to develop a fracture than healthy 
age-matched controls [35].
In particular, Shahinian et al. retrospectively evaluated the 
fracture risk of 50,613 PC patients listed in the Surveillance 
Epidemiology and End Results (SEER) programme between 
1992 and 1997. Among men who survived at least 5 years 
after PC diagnosis, those receiving ADT exhibited a signifi-
cantly higher risk of fracture, as compared to untreated men 
(19.4 vs. 12.6%, p < 0.001). Moreover, patients undergoing 
orchiectomy or receiving at least nine doses of LHRH ago-
nists had the lowest fracture-free survival, although the anal-
ysis did not exclude bone metastasis-related fractures [36].
Another similar analysis involved 11,661 patients with 
non-metastatic PC and confirmed the significantly higher 
fracture rate in men undergoing ADT (7.88 vs. 6.51%/year 
of controls, p < 0.001), and the highest hazard ratio (HR) in 
those receiving LHRH agonists for at least 12 months (1.16, 
95% CI 1.08–1.26; p < 0.001). Interestingly, when consider-
ing fractures at specific sites, both vertebral and hip/femur 
ones were more frequent in patients undergoing ADT, as 
compared to controls (p < 0.001 and p = 0.002, respectively) 
[37].
Not only are such events associated with subsequent 
fractures and loss of independence, but they also represent 
an independent adverse predictor of survival. Indeed, the 
relative risk of death is sevenfold greater in men with PC 
receiving ADT and who have a previous fracture compared 
to those with no fracture history [38].
Bone Loss in BC
Since the early 1990s, although the incidence of BC has 
steadily risen, BC mortality has progressively decreased. 
This “good news” has, however, raised concerns about the 
possible long-term effects of cancer treatments. In particular, 
both chemotherapy and hormone treatment have an impact 
on bone health, with different mechanisms that will be dis-
cussed in the next sections.
Pathophysiology of Chemotherapy‑Induced Bone 
Loss and Clinical Data
Adjuvant chemotherapy has a significant impact on bone 
health in BC, due to both the induction of premature 
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menopause and direct effects on bone turnover [39]. For 
example, cyclophosphamide exerts gonadotoxic effects (the 
metabolite phosphoramide mustard damages at first granu-
losa cells and then oocytes in a dose-dependent manner) [40] 
and also affects cell division of both osteoclast and osteoblast 
precursors, thus interfering with physiological bone turnover 
[41]. Additionally, doxorubicin, although less gonadotoxic, 
can also induce both premature ovarian failure in vivo [42] 
and increased osteoclast differentiation in vitro, at the expense 
of osteoblasts [43].
Studies investigating the effects of adjuvant chemotherapy 
on BMD in women with early BC have all reported a decrease 
in lumbar spine (LS) BMD, as compared to baseline [44–47]. 
In particular, Shapiro and coworkers investigated the effects 
of adjuvant chemotherapy (containing cyclophosphamide 
and/or doxorubicin) on the bone health of 49 premenopausal 
patients with early BC; interestingly, all women experienc-
ing premature ovarian failure (35/49) showed a significant 
BMD reduction at the LS within the first 6 months (− 4.0%, 
p = 0.0001); this was greater than the bone loss seen in women 
who retained menses (− 1.0%) [44].
In another study conducted by Cameron et al., 41 pre-
menopausal patients received adjuvant chemotherapy for 
early BC and were monitored in their bone health and ovar-
ian function for 1 year. During the first 6 months, all patients 
experienced LS BMD decrease (p < 0.0001), independently 
of age, ovarian function and type of chemotherapy; during 
the following 6 months, LS BMD further decreased only in 
women experiencing amenorrhea and/or low estradiol levels 
(p < 0.0001) [47].
A recent prospective study reported BMD changes in 
97 women (mean age: 53 years) with early BC who had 
completed anthracycline- or taxane-based adjuvant chemo-
therapy [48]. All patients received high-dose prednisolone 
as antiemetic prophylaxis and supplementation with calcium 
and vitamin D. At completion of chemotherapy, BMD at LS 
increased significantly in postmenopausal women compared 
to baseline (+ 2.35%, 95% CI 1.6–3.3, p < 0.001), whereas 
the BMD of premenopausal women did not change. Such 
effects could be partially explained by the vitamin supple-
mentation which could prevent the typical calcium defi-
ciency occurring in postmenopausal women.
Based on these data, chemotherapy-induced bone loss is 
currently interpreted more as the consequence of premature 
ovarian failure, rather than the result of direct bone damage.
Pathophysiology of Hormone Treatment‑Induced 
Bone Loss and Clinical Data
Long‑Acting Gonadotropin‑Releasing Hormone Agonists
Long-acting gonadotropin-releasing hormone (GnRH) ago-
nists may be administered to premenopausal individuals 
with hormone receptor-positive (HR+) BC. Persistent 
activation of GnRH receptors leads to their desensitisation 
and consequent suppression of ovarian function. Induction 
of hypogonadism in premenopausal women is associated 
with accelerated bone loss which is usually, at least in part, 
reversible once treatment is stopped, especially in those who 
resume menses [49].
The Zoladex Early Breast Cancer Research Association 
(ZEBRA) bone sub-study included 96 women with pre-
menopausal node-positive BC who had been randomised to 
receive either goserelin or CMF chemotherapy (cyclophos-
phamide, methotrexate and 5-fluorouracil). After 2 years 
of hormone treatment, goserelin was associated with a 
significantly greater reduction in BMD at both LS (mean 
BMD loss − 10.5 vs. − 6.5%, p = 0.0005) and femoral neck 
(FN) (− 6.4 vs. − 4.5%, p = 0.04), as compared to the CMF 
group. After a 3-year follow-up, partial BMD recovery was 
observed in goserelin-treated patients, but this did not occur 
in the CMF group [50].
However, the strongest evidence of goserelin impact on 
bone health derives from the Austrian Breast and Colorectal 
Cancer Study Group trial-12 (ABCSG-12), in which 404 
premenopausal women with BC were randomised to receive 
adjuvant hormone treatment with or without zoledronate. 
Endocrine therapy consisted of either goserelin + tamoxifen 
or goserelin + anastrozole combination and, once admin-
istered without the bisphosphonate (BP), was associated 
with significant BMD reduction, evaluated after 36 and 60 
months and compared to baseline values (after 36 months: 
LS BMD − 11.3%, FN BMD − 7.3%, p < 0.0001 in both 
instances; after 60 months: LS BMD − 6.3%, FN BMD 
− 4.1%, p = 0.0001 and p = 0.058, respectively). On the other 
hand, women receiving zoledronate exhibited stable and 
increased BMD after 36 and 60 months, respectively [51].
Tamoxifen
Tamoxifen is a selective oestrogen receptor modulator 
(SERM) exerting both antagonist (breast) and partial agonist 
effects (bone and uterus), that is widely used as treatment 
for women with HR + BC and as chemoprevention in women 
at high risk for developing BC. A placebo-controlled BC 
chemoprevention trial investigated the effects of tamoxifen 
on bone health in 179 women. In premenopausal women 
treated with tamoxifen, there was a mean annual BMD loss 
of 1.44% at LS, compared with a gain of 0.24% in the pla-
cebo group (p < 0.001). Tamoxifen had the opposite effect 
in postmenopausal patients, in whom it was associated with 
increased BMD at the LS (mean annual increase of 1.17%) 
compared with placebo (insignificant BMD loss) [52]. Sub-
sequent studies involving postmenopausal women treated 
with tamoxifen reported reductions in bone turnover mark-
ers (BTM) [53] and significantly increased LS trabecular 
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bone score (TBS), a novel parameter which reflects bone 
microarchitecture and is associated with resistance to frac-
tures [54].
Aromatase Inhibitors
Third-generation aromatase inhibitors (AIs) induce a rapid 
decrease in circulating estradiol levels by preventing the con-
version of androgens to oestrogens. Therefore, they represent 
a standard adjuvant treatment for postmenopausal patients 
with HR+ BC. Steroidal AIs (e.g. exemestane) irreversibly 
bind to the aromatase enzyme, while non-steroidal AIs (e.g. 
anastrozole, letrozole) are competitive inhibitors which bind 
to the heme moiety of the aromatase cytochrome P450 com-
plex [55]. Table 1 summarises the most important studies 
investigating the effects of AIs on bone health.
The ATAC trial investigated the effects of adjuvant anas-
trozole on bone health [56]. The study reported an increased 
fracture risk in patients treated with anastrozole, as com-
pared to tamoxifen (2.93 vs. 1.90% annual fracture rate, 
p < 0.0001). However, after the treatment was suspended, 
anastrozole-treated patients experienced BMD recovery at 
LS and no further loss at the hip, suggesting that AI-induced 
bone loss is reversible [57, 58].
Adjuvant letrozole has been found to be associated with 
an increase in annual (2.71 vs. 1.87%) and overall frac-
tures (9.3 vs. 6.5%) when compared with tamoxifen [59]. 
The MA17 trial included over 5000 women and confirmed 
that the addition of letrozole, after standard 5-year adjuvant 
therapy with tamoxifen, was associated with significantly 
improved disease-free survival (DFS) in postmenopausal 
women [60]. However, as compared to placebo, letrozole 
was also associated with a slightly increased incidence of 
osteoporosis (5.8 vs. 4.5%, p = 0.07), although the rates of 
fracture were similar in the two treatment groups.
In the Intergroup Exemestane Study (IES), postmeno-
pausal women completing 2–3 years of adjuvant tamoxifen 
were randomised to continue the treatment until the fifth 
year or switch to exemestane. Those in the exemestane arm 
experienced a greater decrease in BMD and, in the intention-
to-treat population, higher annual fracture incidence than 
those who continued to take tamoxifen (2.01 vs. 1.60% with 
tamoxifen) [61]. Fracture rates associated with the use of 
non-steroidal and steroidal AIs appear to be similar [62].
A recent retrospective study evaluated LS BMD and TBS 
variations in 321 non-osteoporotic patients treated with AIs 
for at least 3 years. Both parameters significantly decreased 
from baseline to 5 years (− 6.15 and − 2.12%, respectively; 
p < 0.001 in both instances) although the annual reduction 
tended to slow after 3 and 1 years of treatment, respectively 
[63].
An interesting line of current research aims to investi-
gate CYP19A1 (aromatase) gene polymorphisms potentially 
associated with higher susceptibility to AI-induced bone 
loss. It has been reported that G-to-A substitution at Val80 
in the exon 3 (rs700518) is apparently related to signifi-
cant BMD decrease at LS and hip at 12 months [64]. More 
recently, a significant correlation between another polymor-
phism (rs4646, GG genotype) and osteoporosis during AI 
treatment has been described [65].
Guidelines for Bone Health Assessment
Prostate Cancer
European guidelines for PC were published jointly by the 
European Association of Urology (EAU), International 
Society of Geriatric Oncology (SIOG) and European 
Society for Radiotherapy and Oncology (ESTRO) in 2016 
[66]. These recommend that all men starting long-term 
ADT should undergo dual-energy X-ray absorptiometry 
(DXA) assessment and the result used in conjunction with 
the  FRAX® tool to evaluate individual fracture risk. The 
 FRAX® tool is based upon data from prospectively stud-
ied population cohorts [67]. This tool is available online 
Table 1  Clinical trials investigating the effects of aromatase inhibitors on fracture incidence
AI aromatase inhibitor
Clinical trial Number of 
patients
Experimental arm Control arm Overall/annual fracture incidence References
ATAC 9366 Anastrozole Tamoxifen Overall: 11 vs. 7.7%
Annual: 2.93 vs. 1.90%
[57, 58]
IBIS II bone sub-study 1410 Anastrozole Placebo Annual: 1.37 vs. 1.26% [100]
BIG 1.98 4895 Letrozole Tamoxifen Overall: 9.3 vs. 6.5%
Annual: 2.71 vs. 1.872%
[59]
MA-17 5187 Letrozole Placebo Overall: 3.6 vs. 2.9% [60]
IES 4274 Exemestane Tamoxifen Overall: 7 vs. 5%
Annual: 2.01 vs. 1.60%
[61]
ABCSG-18 3420 AI + denosumab AI + placebo Overall: 5 vs. 9.6% [107]
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and may be used for individuals aged 40–90 years across 
multiple countries and regions of the world to predict the 
10-year risk of hip and major osteoporotic fractures, on 
the basis of multiple risk factors (e.g. age, sex, smoking, 
alcohol intake, history of fractures, familiar history of hip 
fractures, body mass index < 20 kg/m2, long-term use of 
corticosteroids, comorbidities, BMD).
However, these guidelines lack specific recommenda-
tions regarding the ongoing monitoring and follow-up of 
CTIBL. Previous EAU guidelines suggested that the ini-
tial T score should guide the frequency of BMD measure-
ment at the time of ADT initiation (DXA to be repeated 
annually if the T score is between − 2.5 and − 1.0 at base-
line, or every 2 years if the initial T score is above − 1.0) 
[68]. The International Society for Clinical Densitometry 
suggests that BMD measurement should be repeated after 
the first year of ADT, which seems appropriate given that 
the most rapid decline in BMD is observed during the 
first year of therapy [69].
Despite available guidelines, the timing and frequency 
of DXA assessments in men with PC are subject to sig-
nificant variation and depend upon clinician awareness 
and preferences, access to DXA scans and patient factors. 
There is a need for comprehensive and consistent guid-
ance for both the initial and the long-term management of 
bone health in men with PC receiving ADT.
Breast Cancer
Both the European Society for Medical Oncology 
(ESMO) and the American National Comprehensive Can-
cer Network (NCCN) recommend bone health assessment 
in women with iatrogenic premature ovarian failure and 
in patients treated with AIs for BC [70, 71]. The baseline 
evaluation should include a careful history to identify 
risk factors for fragility fractures [39, 72]. DXA assess-
ment of BMD is recommended at baseline and should be 
repeated periodically, according to the local guidelines 
for osteoporosis management. The  FRAX® tool is also 
useful to estimate the 10-year risk of fracture [67]; how-
ever, the algorithm does not include cancer treatment as 
a risk factor. Further information may be provided by 
laboratory assessment including calcium, phosphate, 
vitamin D, parathyroid hormone (PTH) and creatinine 
clearance. Bone biomarkers (such as serum bone alkaline 
phosphatase and urinary N-telopeptide of type I collagen) 
have been investigated for their ability to predict osteopo-
rosis and fragility fractures in BC [73], but their routine 
use in clinical practice is currently limited by the high 
inter- and intra-individual variability.
Management of CTIBL
CTIBL in Prostate Cancer
Lifestyle Measures
Both smoking and excessive alcohol intake are associ-
ated with reduced BMD and should be avoided [74]. Other 
consequences of ADT are sarcopenia and fatigue, both of 
which increase the likelihood of frailty, falls and fractures 
[75]. Regular exercise is helpful to minimise this risk, and 
supervised aerobic and resistance exercise programmes, 
performed at least twice a week for 12 weeks, are currently 
recommended for all men undergoing ADT [76–78].
Calcium and Vitamin D Supplementation
Men with PC are frequently deficient in both calcium and 
vitamin D [79]. Since vitamin D deficiency in men receiv-
ing ADT is independently associated with spinal fractures 
[80], supplementation with calcium and vitamin D should be 
considered in all men receiving ADT. However, the recom-
mended doses (500–1000 mg calcium and 200–500 IU vita-
min D per day) may be insufficient to prevent bone loss [81]. 
Further intervention studies to determine both the safety and 
efficacy of higher doses are required.
Bone‑Targeted Agents (BTAs)
BTAs have an important role in the management of CTIBL. 
Bisphosphonates (BP) have high affinity for mineralised 
bone matrix, where they bind selectively to hydroxyapatite 
and are released during resorption. Ingestion of BP by osteo-
clasts results in their inhibition, either through induction of 
apoptosis (non-nitrogen-containing BP such as clodronate) 
or through inhibition of the mevalonate pathway required 
for osteoclastogenesis (nitrogen-containing BP such as zole-
dronate, ibandronate and pamidronate). Many BP are admin-
istered orally; however, the most comprehensively studied 
is zoledronate which is given intravenously. It requires 
dosage adjustment in patients with a creatinine clearance 
(CrCl) < 60 ml/min and is contraindicated in severe renal 
impairment (CrCl < 30 ml/min).
Denosumab is another BTA approved for the treatment 
of CTIBL. It is a fully humanised monoclonal IgG2 anti-
body that targets RANK-L and prevents its interaction with 
RANK on osteoclast precursors. Consequent inhibition of 
osteoclast differentiation and activation causes a rapid reduc-
tion in bone resorption [82].
Other antiresorptive drugs are currently widely used for 
the management of non-malignant bone disease, but are 
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not specifically recommended in the CTIBL setting. These 
include calcitonin (the clinical investigation of which in 
cancer patients has been very limited) and teriparatide, a 
recombinant human PTH analogue. Teriparatide has been 
associated with an increased risk of osteosarcoma in patients 
receiving bone radiotherapy and is contraindicated for the 
treatment of CTIBL [83].
The potential role of SERM for the prevention of ADT-
induced bone loss has been widely investigated by Smith 
and coworkers. In particular, 12-month treatment with either 
raloxifene [84] or toremifene [85] turned out to be capable 
to increase BMD at all sites, while reducing BTM levels, in 
men with non-metastatic PC undergoing ADT. When admin-
istered for 24 months, toremifene induced a 50% reduction 
in new vertebral fractures and significantly decreased the 
risk of fractures at all sites (p < 0.05 in both instances), as 
compared to placebo [86].
The role of denosumab in men with PC was evaluated in a 
randomised study of 1468 men receiving ADT for localised 
PC. Denosumab increased LS BMD by 5.6%, whereas those 
in the placebo group experienced a 1.0% loss (p < 0.001) 
[87]. Denosumab was also associated with a reduction in 
the incidence of new vertebral fractures after 36 months 
of treatment (1.5 vs. 3.9% with placebo; RR 0.38; 95% CI 
0.19–0.78), and with a non-significant reduction in fractures 
at any site. Importantly, there were no between-group differ-
ences in adverse events.
Several studies have investigated the ability of BP to pre-
vent CTIBL associated with ADT. BP have been found to 
increase LS and hip BMD when compared to placebo, and 
also to be associated with a significant reduction in BTM 
[88–92]. However, available evidence is limited by small 
patient numbers, heterogeneous populations, variations in 
the type and frequency of BP administration and different 
schedules of follow-up, all of which preclude effective meta-
analysis. No study had sufficient power to detect differences 
in the incidence of fractures between groups. Only one non-
randomised study of 94 patients attempted to compare the 
efficacy of different BP [93]. Large, prospective randomised 
studies of BP in men receiving ADT are necessary in order 
to determine the efficacy of BP for fracture prevention in 
this setting.
Guidelines for the Use of BTA in PC
European guidelines are available to guide the approach 
to CTIBL in PC patients [70]. These include a treatment 
algorithm for assessment and management of bone health 
(Fig. 1). Although a range of BP have been shown to prevent 
bone loss in men with locally advanced PC receiving ADT, 
denosumab is currently the only BTA that is licensed for the 
prevention of CTIBL in PC.
CTIBL in BC
Lifestyle Measures
Limitation of alcohol consumption and smoking cessation 
are recommended. Moderate weight-bearing exercise should 
be practised regularly to take advantage of the beneficial 
effects of exercise on BMD [94].
Calcium and Vitamin D Supplementation
If dietary intake is inadequate, calcium supplementation 
is recommended (1000 mg/day) together with vitamin D 
supplementation (800–1000 IU/day). Concomitant steroid 
uptake interferes with vitamin D absorption and requires 
higher dosage [39, 95]. Elderly patients, and those with 
reduced sunlight exposure and/or physical activity, should 
be assessed for vitamin D serum levels and deficient levels 
treated with high-dose vitamin D followed by ongoing sup-
plementation [94].
BTA
Several clinical trials have investigated the role of BP in 
the management of BC-associated CTIBL; the most impor-
tant are summarised in Table 2. The earliest results came 
from small studies exploring the efficacy of oral clodronate. 
Postmenopausal women treated with adjuvant tamoxifen or 
toremifene were randomised to the clodronate or control 
group for 3 years, where clodronate was associated with 
a small BMD improvement at both LS (+ 1.0 vs. − 1.7%, 
p = 0.01) and FN (+ 2.4 vs. − 0.4%, p = 0.12), as compared 
to patients not receiving the BP [96].
The ARIBON trial reported that 2-year treatment with 
ibandronate induced a significant BMD gain at both LS and 
hip (+ 2.98 and + 0.60%, p < 0.01 for both) in osteopaenic 
postmenopausal women treated with adjuvant anastrozole 
[97]. Patients who continued ibandronate treatment up to 
5 years underwent a mean lumbar BMD increase of + 3.19%, 
while those stopping the BP showed a BMD reduction at 
both LS (− 3.21%) and hip (− 5%) at the 5-year follow-up 
[98].
The efficacy of oral risedronate in postmenopausal 
women was investigated in both the SABRE trial and the 
IBIS II study. SABRE reported that those at moderate or 
high risk of fragility fractures significantly benefited from 
the addition of risedronate to adjuvant AI treatment [99]. 
IBIS II investigated the effect of anastrozole or placebo 
for BC prevention in women who were at high risk of BC. 
Those with osteopaenia or osteoporosis at baseline were 
included in a sub-study to assess bone protection with 
risedronate. After 3 years, the addition of risedronate to 
anastrozole was associated with a 1.1% (95% CI 0.2–2.1) 
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increase in LS BMD compared to a 2.6% (95% CI − 4.0 
to − 1.3) decrease with placebo (p < 0.0001) in osteopae-
nic women; among osteoporotic patients, those receiv-
ing placebo and risedronate experienced a greater gain 
in BMD at LS (3.9 vs. 1.2%, p = 0.006) and hip (1.5 vs. 
0.3%, p = 0.12) than those treated with anastrozole with 
risedronate, but the BP still counterbalanced the AI-
induced bone loss [100].
Zoledronate is the most extensively investigated intrave-
nous BP in the CTIBL setting, both in pre- and postmeno-
pausal patients. In the bone sub-protocol of the ABCSG-
12 trial, 404 premenopausal women were randomised to 
Fig. 1  Algorithm for the assessment and management of cancer 
treatment-induced bone loss [70]. a Aromatase inhibitors and ovar-
ian suppression therapy/oophorectomy for BC and androgen depri-
vation therapy for prostate cancer. b If patients experience an annual 
decrease in BMD of ≥ 10% (or ≥ 4–5% in patients who were osteo-
penic at baseline) using the same DXA machine, secondary causes 
of bone loss such as vitamin D deficiency should be evaluated and 
antiresorptive therapy initiated. Use lowest t score from spine and 
hip. c Six monthly intravenous zoledronate, weekly oral alendronate 
or risedronate or monthly oral ibandronate acceptable. d Denosumab 
may be a potential treatment option in some patients. e Although 
osteonecrosis of the jaw is a very rare event with bone protection 
doses of antiresorptives, regular dental care and attention to oral 
health are advisable. BMD bone mineral density, BMI body mass 
index, DXA dual-energy X-ray absorptiometry
Table 2  Clinical trials investigating the efficacy of bisphosphonates in preventing AI-induced CTIBL
BMD bone mineral density, LS lumbar spine, ZA zoledronic acid
Clinical trial No. of patients Follow-
up period 
(months)
Experimental arm Control arm BMD variations at LS References
ARIBON 131 24 Anastrozole + iban-
dronate
Anastrozole + placebo + 2.98 vs. − 3.22% [98]
SABRE 234 24 Anastrozole + rise-
dronate
Anastrozole + placebo + 2.2 vs. − 1.8% [99]
IBIS II bone sub-study 1410 36 Anastrozole + rise-
dronate
Anastrozole + placebo + 1.1 vs. − 2.6% [100]
Z-FAST 602 61 Letrozole + upfront ZA Letrozole + upfront ZA + 6.18–6.22 vs. 
− 2.42%
[101]
ZO-FAST 1065 60 Letrozole + upfront ZA Letrozole + delayed ZA + 4.3 vs. − 5.4% [102]
E-ZO-FAST 527 12 Letrozole + upfront ZA Letrozole + delayed ZA + 2.72 vs. − 2.71% [103]
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receive hormone treatment (goserelin + anastrozole vs. 
goserelin + tamoxifen) with or without zoledronate. After 
3 years, patients receiving the BP exhibited stable BMD 
at both LS and trochanter (+ 0.4 and + 0.8%, respectively), 
while at 60 months zoledronate treatment was associated 
with BMD increases at both sites, compared to baseline 
(4.0% at LS, p = 0.02; 3.9% at trochanter, p = 0.07) [51]. 
Those who received endocrine therapy alone experienced 
significant bone loss at both time-points, with the greatest 
loss being observed in the goserelin + anastrozole arm.
In postmenopausal women undergoing AI therapy, 
the Z-FAST, ZO-FAST and E-ZO-FAST trials compared 
upfront zoledronate treatment (4 mg every 6 months) with 
delayed administration, started after the detection of frac-
tures or BMD decrease. At the final analyses, all these stud-
ies showed significantly higher BMD values in the “upfront” 
arms at LS, FN and hip, as compared to “delayed-treatment” 
groups [101–103]. In agreement with these data, Wagner-
Johnston et al. described that upfront zoledronate addition 
to letrozole treatment, in postmenopausal patients previ-
ously treated with tamoxifen, was less frequently associated 
with LS BMD decrease as compared to delayed therapy. 
This difference was statistically significant after 5 years 
(p < 0.0001), while there were no significant differences 
in osteoporosis and fracture occurrence [104]. A recent 
study has also described a significant increase in LS BMD 
(+ 11.6%, p = 0.01) when zoledronate was given alongside 
adjuvant AI in women with pre-existing osteopaenia or 
osteoporosis [105].
Denosumab has also been investigated for its role in the 
prevention of AI-induced bone loss. In an initial randomised 
phase II study, 252 women with early HR + BC were ran-
domised to receive an AI with or without denosumab (60 mg 
every 6 months for 2 years), and those in the denosumab arm 
experienced higher BMD gains at multiple sites, compared 
to controls [106]. The subsequent ABCSG-18 phase III trial 
prospectively evaluated the effects of adjuvant denosumab 
in postmenopausal patients with early HR + BC receiving 
AIs. A total of 3420 women were randomised to receive 
either denosumab or placebo every 6 months. Denosumab 
was associated with a significantly delayed time to first frac-
ture and a reduced fracture incidence, compared to placebo 
(independently of baseline BMD) [107]. However, after den-
osumab discontinuation a rebound effect with accelerated 
bone loss was described [108, 109] leading to the proposal 
of a sequential BP administration to retain BMD values.
Guidelines for the Use of BTAs in BC
Current guidelines recommend adjuvant BTA treatment 
in those with a baseline t score < − 2 or at least two risk 
factors for fractures [110]. A panel of bone experts rep-
resenting the major international societies that promote 
bone health and research (i.e. International Osteoporosis 
Foundation, IOF; Cancer and Bone Society, CABS; Euro-
pean Calcified Tissue Society, ECTS; International Expert 
Group for AIBL, IEG; European Society for Clinical and 
Economics Aspects of Osteoporosis, Osteoarthritis and 
Musculoskeletal Diseases, ESCEO; International Meno-
pause Society, IMS) has recently published a position 
statement that recommends BTA administration also to 
patients with a baseline t score < − 1.5 with an additional 
risk factor for fracture, while those women with a base-
line t score > − 2 and no fracture risk factors should be 
managed according to the BMD variations which occurred 
during the first year of AI treatment [94]. There is no con-
sensus about the optimal treatment duration, but the Can-
cer Care Ontario (CCO) and American Society of Clini-
cal Oncology (ASCO) guidelines do not recommend the 
administration of zoledronate for more than 5 years, while 
clodronate should be given for up to 3 years [111].
In premenopausal patients undergoing ovarian suppres-
sion, 4 mg zoledronate every 6 months is recommended 
in addition to calcium and vitamin D supplementation. In 
postmenopausal women, either oral or intravenous BP have 
proven efficacious in preventing bone loss during AI treat-
ment, and thus the treatment choice should depend upon 
local guidelines, the different toxicity profiles and concur-
rent therapies [49, 70]. Further clinical trials are needed to 
compare different BP doses and schedules [111].
Compliance to oral BP should be regularly assessed and, 
if unsatisfactory, switching to an intravenous BTA should 
be considered [94].
A recent prospective study investigated adherence to 
CTIBL treatment guidelines by both patients and clinicians. 
Vitamin D and calcium supplementation was prescribed in 
three quarters of those receiving AIs, but failure to comply 
with guidelines was identified in 11.6% of cases. A total of 
12% (54 of 438 patients) received a BP, but seven patients 
who were osteoporotic did not receive antiresorptive medi-
cation [112]. These data underline the need for clarification 
and improved awareness of current guidelines.
There is still a debate about the administration of deno-
sumab in the adjuvant setting; European bone experts sug-
gest that it might be offered at the same dosage adminis-
tered to patients with osteoporosis [49], while US clinicians 
underline the need for more consistent data, before making 
any recommendation [111].
Recent evidence suggests that adjuvant BP also reduce 
bone recurrence and improve survival in postmenopausal 
patients with BC [113]. Although the routine use of BP 
in this setting has not received regulatory approval, bone 
experts and oncologists recommend their administration 
to postmenopausal women with intermediate/high risk of 
BC (T2-4, N1-3, grade 2–3, ER negative or Her2 positive), 
regardless of BMD values [110, 111].
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BTA Safety
BTAs are generally well tolerated, especially at the dosage 
recommended for CTIBL prevention [70].
Intravenous BP, such as zoledronate, seem to be more 
frequently associated with acute phase reactions than the 
oral ones. Symptoms include transient bone pain, arthralgia 
or myalgia, fever and nausea [111]. On the other hand, oral 
BP can cause esophagitis and other gastrointestinal disor-
ders; for this reason, it is advised to take them on an empty 
stomach and remain upright for at least 30 min [111].
Hypocalcaemia is more likely to occur during denosumab 
treatment but can easily be prevented by the regular monitor-
ing of serum calcium levels and the concomitant administra-
tion of calcium and vitamin D supplements [70].
Osteonecrosis of the jaw (ONJ) is one of the most impor-
tant adverse events occurring during BTA treatment. How-
ever, it is more common (incidence of approximately 1.3%) 
in bone metastatic patients who receive BTAs on a monthly 
basis, rather than those undergoing less intensive treatment 
for osteoporosis or CTIBL management [49].
Nevertheless, a careful dental examination and appro-
priate preventive dentistry are recommended before BTA 
administration, and patients should be advised to maintain 
good oral hygiene. If possible, invasive dental procedures, 
such as tooth extractions and implants, should be avoided 
during BTA treatment [49, 70].
Conclusion
The improved survival of patients with BC and PC has led 
to increasing awareness of survivorship issues, including the 
long-term consequences of cancer treatment. Current treat-
ments for both BC and PC adversely affect bone health via 
several mechanisms, increasing the risk of osteoporosis and 
fracture. These potentially devastating complications may 
be avoided by lifestyle changes and the use of BTAs, with 
zoledronate and denosumab being the most comprehensively 
studied agents. Zoledronate has been shown to prevent the 
loss of BMD in women with BC who experience premature 
menopause, in postmenopausal women receiving an AI and 
in men with PC undergoing ADT. However, these improve-
ments have unfortunately not been translated into a clear 
reduction in fracture incidence. Denosumab is licensed for 
the prevention of CTIBL due to its proven ability to reduce 
the incidence of fractures and has become the treatment of 
choice for patients at high risk of fracture. Recently pub-
lished guidelines are available to guide the assessment and 
treatment of CTIBL in both PC and BC. There is a need to 
improve awareness of CTIBL amongst clinicians and mem-
bers of the multidisciplinary team, in order to ensure that 
these are widely and consistently implemented in clinical 
practice and that patients receive the best possible treatment.
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